Abstract:Immune checkpoint inhibitors targeting programmed cell death protein 1, programmed death-ligand 1, and cytotoxic T-lymphocyte-associated protein 4 provide deep and durable treatment responses which have revolutionized oncology. However, despite over 40% of cancer patients being eligible to receive immunotherapy, only 12% of patients gain benefit. A key to understanding what differentiates treatment response from non-response is better defining the role of the innate immune system in anti-tumor immunity and immune tolerance. Teleologically, myeloid cells, including macrophages, dendritic cells, monocytes, and neutrophils, initiate a response to invading pathogens and tissue repair after pathogen clearance is successfully accomplished. However, in the tumor microenvironment (TME), these innate cells are hijacked by the tumor cells and are imprinted to furthering tumor propagation and dissemination. Major advancements have been made in the field, especially related to the heterogeneity of myeloid cells and their function in the TME at the single cell level, a topic that has been highlighted by several recent international meetings including the 2021 China Cancer Immunotherapy workshop in Beijing. Here, we provide an up-to-date summary of the mechanisms by which major myeloid cells in the TME facilitate immunosuppression, enable tumor growth, foster tumor plasticity, and confer therapeutic resistance. We discuss ongoing strategies targeting the myeloid compartment in the preclinical and clinical settings which include: (1) altering myeloid cell composition within the TME; (2) functional blockade of immune-suppressive myeloid cells; (3) reprogramming myeloid cells to acquire pro-inflammatory properties; (4) modulating myeloid cells via cytokines; (5) myeloid cell therapies; and (6) emerging targets such as Siglec-15, TREM2, MARCO, LILRB2, and CLEVER-1. There is a significant promise that myeloid cell-based immunotherapy will help advance immuno-oncology in years to come.

Cell-mediated barriers in cancer immunosurveillance

Expanding horizons in cancer therapy by immunoconjugates targeting tumor microenvironments

Suppressive Myeloid Cells Shape the Tumor Immune Microenvironment

Cracking the Codes behind Cancer Cells' Immune Evasion

Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness

Immune Cells Within the Tumor Microenvironment: Biological Functions and Roles in Cancer Immunotherapy

Barriers to immune cell infiltration in tumors

Understanding of Immune Escape Mechanisms and Advances in Cancer Immunotherapy.

Immunosuppressive Strategies that are Mediated by Tumor Cells

Cancer-Associated Fibroblasts and Tumor-Associated Macrophages in Cancer and Cancer Immunotherapy

Cell-mediated immune resistance in cancer

Immunocytes interact directly with cancer cells in the tumor microenvironment: one coin with two sides and future perspectives

Cancer-associated mesenchymal stem/stromal cells: role in progression and potential targets for therapeutic approaches

Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy

Role of cancer‐associated fibroblast subpopulations in immune infiltration, as a new means of treatment in cancer

Cancer-Associated Fibroblast Mediated Inhibition of CD8+ Cytotoxic T Cell Accumulation in Tumours: Mechanisms and Therapeutic Opportunities

Systemic immunity in cancer

Tumor-Derived Extracellular Vesicles in Cancer Immunoediting and Their Potential as Oncoimmunotherapeutics

T cell dysfunction and therapeutic intervention in cancer

Modulation of T cell function and survival by the tumor microenvironment

Immune evasion in cell-based immunotherapy: unraveling challenges and novel strategies